Atara Biotherapeutics, Inc.
http://www.atarabio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Atara Biotherapeutics, Inc.
Pierre Fabre Fights Off Rivals For Rights To Atara's Allogeneic T-Cell Therapy
After paying $45m upfront, the French firm has beaten off considerable competition to seal the European, Middle East and African rights to tabelecleucel which will be filed next month for Epstein-Barr virus-positive post-transplant lymphoproliferative disease.
EU Accelerated Assessment Tracker
The Pink Sheet's EU accelerated assessment tracker has been updated to include developments relating to experimental products from Atara, Calliditas, and Roche.
Tab-Cel Gets EU Fast-Track Nod; Nefecon Reverts To Standard Review
The outcomes of a handful of requests for accelerated assessment at the European Medicines Agency appear not yet to be in the public domain. In the meantime, there's been good for news for Atara's tab-cel and a switch to standard review for Nefecon from Calliditas.
Roche Among EU Fast-Track Hopefuls With Lymphoma Bispecific Mosunetuzumab
Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Nina Biotherapeutics, Inc.
- Pinta Biotherapeutics, Inc.
- Santa Maria Biotherapeutics, Inc.